7115-91-5

Usage

Uses

Used in Organic Chemistry:
ETHYL 2-(BROMOMETHYL)BENZOATE is used as a building block for the synthesis of biologically active molecules, given its versatile reactivity and ability to engage in a wide range of organic reactions.
Used in Pharmaceutical Industry:
In the pharmaceutical sector, ETHYL 2-(BROMOMETHYL)BENZOATE is utilized as a key intermediate in the production of various drugs, contributing to the development of new medicinal compounds.
Used in Agrochemical Industry:
ETHYL 2-(BROMOMETHYL)BENZOATE is employed as a precursor in the synthesis of agrochemicals, playing a crucial role in the creation of pesticides and other agricultural products to enhance crop protection and yield.
Used in Chemical Manufacturing:
ETHYL 2-(BROMOMETHYL)BENZOATE is used as a valuable component in the manufacturing of various products across different industries, leveraging its reactivity and functional group for diverse applications.

InChI:InChI=1/C10H11BrO2/c1-2-13-10(12)9-6-4-3-5-8(9)7-11/h3-6H,2,7H2,1H3

Upstream product

• 64-17-5 ethanol 
• 40819-28-1 2-(bromomethyl)benzoyl bromide 
• 118-90-1 ortho-methylbenzoic acid 
• 7115-89-1 2-(bromomethyl)benzoic acid 
• 20924-53-2 ethyl <(2-carbethoxybenzyl)oxy>acetate 
• 75-16-1 methylmagnesium bromide 
• 487-97-8 1-ethoxy-1,3-dihydroisobenzofuran-1-ylium borofluorate 
• 87-24-1 ethyl 2-methylbenzoate 
• 934-01-0 2-bromobenzocyclobutenone 
• 7115-90-4 α-Bromo-o-toluyl Chloride 

Downstream Products

• 861363-10-2 3-(2-ethoxycarbonyl-phenyl)-2-cyano-propionic acid ethyl ester 
• 88550-19-0 benzoic acid 2-methoxy-methyl ester 
• 96259-60-8 ethyl 2-(ethoxymethyl)benzoate 
• 409109-51-9 2-phthalimidomethyl-benzoic acid ethyl ester 
• 118-90-1 ortho-methylbenzoic acid 
• 87-41-2 2-benzofuran-1(3H)-one 
• 7115-92-6 2-Aethoxycarbonylaminooxymethyl-benzoesaeureaethylester 
• 130569-91-4 1-(2-ethoxycarbonylbenzyl)pyrrole 
• 145103-21-5 2-(2-Benzoyl-1-cyan-1,2-dihydro-6,7-dimethoxy-1-isochinolylmethyl)-benzoesaeureethylester 
• 59636-00-9 (o-ethoxycarbonylbenzyl)triphenylphosphonium bromide 
• 15316-89-9 N-Benzyloxy-N-(2-ethoxycarbonyl-benzyl)-carbamidsaeure-ethylester 
• 168134-59-6 2-ethoxycarbonyl-2-(2-(ethoxycarbonyl)phenylmethyl)-1-indanone 
• 209806-11-1 ethyl 2-(1-piperidinylmethyl)benzoate 
• 209806-14-4 ethyl 2-(N-benzyl-N-methylaminomethyl)benzoate 

Relevant academic research and scientific papers

Metal Complexes with Macrocyclic Ligands Part XXV One-Step Synthesis of Mono-N-substituted Azamacrocycles with a Carboxylic Group in the Side-Chain and their Complexes with Cu2+ and Ni2+

Mono-N-substituted azamacrocycles 2-7, containing a carboxyalkyl or carboxyaryl side-chain, are obtained by reacting a five-fold excess of the macrocycle with 1 equiv. of a suitable halogenocarboxylic acid in alkaline aqueous EtOH.For halogenocarboxylic a

Pyridazone derivative and its uses

The present invention belongs to the pharmaceutical field, specifically relates to a pyridazone derivative and its uses, compounds thereof and pharmaceutically acceptable salts, solvates including hydrates, polycrystallines, prodrugs, co-crystallines, tau

Development of LM98, a Small-Molecule TEAD Inhibitor Derived from Flufenamic Acid

The YAP-TEAD transcriptional complex is responsible for the expression of genes that regulate cancer cell growth and proliferation. Dysregulation of the Hippo pathway due to overexpression of TEAD has been reported in a wide range of cancers. Inhibition of TEAD represses the expression of associated genes, demonstrating the value of this transcription factor for the development of novel anti-cancer therapies. We report herein the design, synthesis and biological evaluation of LM98, a flufenamic acid analogue. LM98 shows strong affinity to TEAD, inhibits its autopalmitoylation and reduces the YAP-TEAD transcriptional activity. Binding of LM98 to TEAD was supported by 19F-NMR studies while co-crystallization experiments confirmed that LM98 is anchored within the palmitic acid pocket of TEAD. LM98 reduces the expression of CTGF and Cyr61, inhibits MDA-MB-231 breast cancer cell migration and arrests cell cycling in the S phase during cell division.

Influenza virus replication inhibitor and uses thereof

The invention belongs to the field of medicines, and particularly relates to a new compound serving as an influenza virus replication inhibitor, a preparation method thereof, a pharmaceutical composition containing the compound, and application of the compound and the pharmaceutical composition in the treatment of influenza. The compound is a compound shown in a formula (I) or a stereoisomer, a tautomer, oxynitride, a solvate, a metabolite, a pharmaceutically acceptable salt or prodrugs of the compound shown in the formula (I). The compound can well inhibit influenza viruses, and/or has lowercytotoxicity, more excellent in-vivo metabolic dynamics properties and in-vivo pharmacodynamic properties.

INFLUENZA VIRUS REPLICATION INHIBITOR AND USES THEREOF

The invention belongs to the field of medicine, and particularly relates to a novel compound as a replication inhibitor of influenza virus and a preparation method thereof, a pharmaceutical composition comprising the compound and use of the compound and pharmaceutical composition thereof in treating influenza. The present invention provides a compound having Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, The compound of the present invention can inhibit influenza virus well, and/or has lower cytotoxicity, better in vivo pharmacokinetic properties and in vivo pharmacodynamic properties.

Amine-carbon disulfide promoted synthesis of novel benzo[e][1,3]thiazepin-5(1H)-one derivatives

In this paper, a simple method is introduced for the synthesis of novel 4-substituted-3-thioxo-3,4-dihydrobenzo[e][1,3]thiazepin-5(1H)-one derivatives. The synthesis is based on a two-step reaction of 2-methylbenzoic acid, an amine, and carbon disulfide. In the first step, 2-methylbenzoic acid reacts with sulfuric acid in ethanol, followed by the reaction with N-bromosuccinimide to produce ethyl 2-(bromomethyl)benzoate. Amine and carbon disulfide react in a separate flask in basic medium to give carbamodithioate salt. Carbamodithioate and ethyl 2-(bromomethyl)benzoate react together in dimethylformamide to produce the desired 4-substituted-3-thioxo-3,4-dihydrobenzo[e][1,3]thiazepin-5(1H)-one derivatives. The method is simple and fast and is applicable to a wide variety of substrates and gives the desired products in high isolated yields.

Dihydrodibenzothiepine: Promising hydrophobic pharmacophore in the influenza cap-dependent endonuclease inhibitor

This work describes a set of discovery research studies of an influenza cap-dependent endonuclease (CEN) inhibitor with a carbamoyl pyridone bicycle (CAB) scaffold. Using influenza CEN inhibitory activity, antiviral activity and pharmacokinetic (PK) parameters as indices, structure activity relationships (SAR) studies were performed at the N-1 and N-3 positions on the CAB scaffold, which is a unique template to bind two metals. The hydrophobic substituent at the N-1 position is extremely important for CEN inhibitory activity and antiviral activity, and dihydrodibenzothiepine is the most promising pharmacophore. The compound (S)-13i showed potent virus titer reduction over oseltamivir phosphate in an in vivo mouse model. The CAB compound described herein served as the lead compound of baloxavir marboxil with a tricyclic scaffold, which was approved in Japan and the USA in 2018.

Computer-Assisted Discovery and Structural Optimization of a Novel Retinoid X Receptor Agonist Chemotype

As universal heterodimer partners of many nuclear receptors, the retinoid X receptors (RXRs) constitute key transcription factors. They regulate cell proliferation, differentiation, inflammation, and metabolic homeostasis and have recently been proposed as potential drug targets for neurodegenerative and inflammatory diseases. Owing to the hydrophobic nature of RXR ligand binding sites, available synthetic RXR ligands are lipophilic, and their structural diversity is limited. Here, we disclose the computer-assisted discovery of a novel RXR agonist chemotype and its systematic optimization toward potent RXR modulators. We have developed a nanomolar RXR agonist with high selectivity among nuclear receptors and superior physicochemical properties compared to classical rexinoids that appears suitable for in vivo applications and as lead for future RXR-targeting medicinal chemistry.

Fluorescence-enhanced hydrogen sulfide molecular fluorescent probe and preparation method and application thereof

The invention discloses a fluorescence-enhanced hydrogen sulfide molecular fluorescent probe and a preparation method and application thereof and belongs to the technical field of analytic chemistry. The molecular formula of the probe molecules is C21H14N4O2S. The formula of the probe is as shown in formula (I). The fluorescence-enhanced hydrogen sulfide molecular fluorescent probe has the advantages that the probe is simple to prepare, mature in synthetic route, capable of fast and accurately detecting hydrogen sulfide in cells and achieving fluorescence imaging, applicable to the content sensing detecting of the hydrogen sulfide in water environments and biological cell systems, and promising in application prospect in field of biological molecular detection.

Dibenzo[b,f][1,4]oxazepines and dibenzo[b,e]oxepines: Influence of the chlorine substitution pattern on the pharmacology at the H1R, H4R, 5-HT2AR and other selected GPCRs

Inspired by VUF6884 (7-Chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine), reported as a dual H1/H4 receptor ligand (pKi: 8.11 (human H1R (hH1R)), 7.55 (human H4R (hH4R))), four known and 28 new oxazepine and related oxepine derivatives were synthesised and pharmacologically characterized at histamine receptors and selected aminergic GPCRs. In contrast to the oxazepine series, within the oxepine series, the new compounds showed high affinity to the hH1R (pKi: 6.8–8.7), but no or moderate affinity to the hH4R (pKi: ≤ 5.3). For one oxepine derivative (1-(2-Chloro-6,11-dihydrodibenzo[b,e]oxepin-11-yl)-4-methylpiperazine), the enantiomers were separated and the R-enantiomer was identified as the eutomer at the hH1R (pKi: 8.83 (R), 7.63 (S)) and the guinea-pig H1R (gpH1R) (pKi: 8.82 (R), 7.41 (S)). Molecular dynamic studies suggest that the tricyclic core of the compounds is bound in a similar mode into the binding pocket, as described for doxepine in the hH1R crystal structure. Moreover, docking studies of all oxepine derivatives at the hH1R indicate that the oxygen and the position of the chlorine in the tricyclic core determines, if the R- or the S-enantiomer is the eutomer. For some of the oxazepines and oxepines the affinity to other aminergic GPCRs is in the same range as to hH1R or hH4R, thus, those compounds have to be classified as dirty drugs. However, one oxazepine derivative (3,7-Dichloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine was identified as dual hH1/h5-HT2A receptor ligand (pKi: 9.23 (hH1R), 8.74 (h5-HT2AR), ≤7 at other analysed GPCRs), whereas one oxepine derivative (1-(3,8-Dichloro-6,11-dihydrodibenzo[b,e]oxepin-11-yl)-4-methylpiperazine) was identified as selective hH1R antagonist (pKi: 8.44 (hH1R), ≤6.7 at other analyzed GPCRs). Thus, the pharmacological results suggest that the oxazepine/oxepine moiety and additionally the chlorine substitution pattern toggles receptor selectivity and specificity.